Cormorant Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Cormorant Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-42,500	Closed	-$4.14M	–	87
2015 Q1	$4.14M	Sell	42,500 -57,500	-58%	-$6.09M	0.64%	44
2014 Q4	$9.28M	Hold	100,000	–	–	1.43%	23
2014 Q3	$6.88M	Buy	+100,000	New	+$7.16M	1.41%	18

Cormorant Asset Management's GEVA Position: Q2 2015 in Review

Cormorant Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 42,500 shares — an estimated $4.14M sold.

Cormorant Asset Management first reported a position in GEVA in Q3 2014 and held it in 3 quarters. The position peaked at $9.28M in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

Cormorant Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
Cormorant Asset Management sold 42,500 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $4.14M.
Cormorant Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2014 and held it in 3 quarters.
Cormorant Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $9.28M in Q4 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.